Action Resverlogix - RVX

Resverlogix Corp (RVX) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

0,10

( 5,26% )

Prix Achat

0,09

Prix Vente

0,10

Volume échangé

13 000

0,095 Fourchette du Jour 0,10

0,035 Plage de 52 semaines 0,30

Cap du marché

34,384M

Clôture Veille

0,095

Ouverture

0,095

Dernière Transaction

2000

0.1

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

$ 36 294

Actions en circulation

343 841 709

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-3,36

Bénéfice par action (BPA)

-0,02

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

-6,22M

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, typ... Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada. Show more

Secteur

Healthcare

Industrie

Biotechnology & Life Sciences

Site Web

www.resverlogix.com

Siège social

Calgary, Canada

Fondé

Resverlogix Corp est coté dans le secteur Healthcare de la Toronto Stock Exchange avec le ticker RVX. Le dernier cours de clôture d'Resverlogix était de $0,10. Au cours de la dernière année, les actions de Resverlogix ont été négociées dans une fourchette de prix de $ 0,035 à $ 0,30.

Resverlogix compte actuellement 343 841 709 actions en circulation. La capitalisation boursière d'Resverlogix est de $34,38 million. Resverlogix a un ratio cours/bénéfice (ratio PE) de -3.36.

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF...

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”...

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Appointment of New Chief Scientific Officer

CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation...

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company...

Resverlogix Announces One-Year Extension of Debenture

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”...

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today...

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

CALGARY, Alberta, March 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), a global...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.005	5.26315789474	0.095	0.1	0.095	23959	0.09700346	CS
4	0	0	0.1	0.1	0.085	40279	0.09803094	CS
12	-0.025	-20	0.125	0.125	0.085	32278	0.10313422	CS
26	-0.015	-13.0434782609	0.115	0.135	0.085	33530	0.10602445	CS
52	0.06	150	0.04	0.3	0.035	76742	0.1103608	CS
156	-0.01	-9.09090909091	0.11	0.3	0.035	66115	0.08553092	CS
260	-0.8	-88.8888888889	0.9	0.92	0.035	65625	0.18742417	CS

RVX - Frequently Asked Questions (FAQ)

What is the current Resverlogix Corp share price?

The current share price of Resverlogix Corp is $ 0,10

How many Resverlogix Corp shares are in issue?

Resverlogix Corp has 343 841 709 shares in issue

What is the market cap of Resverlogix Corp?

The market capitalisation of Resverlogix Corp is CAD 34,38M

What is the 1 year trading range for Resverlogix Corp share price?

Resverlogix Corp has traded in the range of $ 0,035 to $ 0,30 during the past year

What is the PE ratio of Resverlogix Corp?

The price to earnings ratio of Resverlogix Corp is -3,36

What is the registered address of Resverlogix Corp?

The registered address for Resverlogix Corp is 4820 Richard Road SW, Calgary, Alberta, T3E 6L1

What is the Resverlogix Corp website address?

The website address for Resverlogix Corp is www.resverlogix.com

Which industry sector does Resverlogix Corp operate in?

Resverlogix Corp operates in the Biotechnology & Life Sciences sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Resverlogix Corp (RVX)

Resverlogix Corp (RVX) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Resverlogix Corp

RVX Dernières nouvelles

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Resverlogix Announces Appointment of New Chief Scientific Officer

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Resverlogix Announces One-Year Extension of Debenture

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

RVX - Frequently Asked Questions (FAQ)

RVX Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Resverlogix Corp (RVX)

Resverlogix Corp (RVX) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Resverlogix Corp

RVX Dernières nouvelles

InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Resverlogix Announces Appointment of New Chief Scientific Officer

Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders

Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Resverlogix Announces One-Year Extension of Debenture

Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine

Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th

RVX - Frequently Asked Questions (FAQ)

RVX Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités